v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Grant Revenue $ 57,480 $ 336,108
Operating Expenses:        
Research and development 131,130 880,835 464,464 1,282,987
General and administrative 807,548 977,373 1,722,117 1,951,790
Total Operating Expenses 938,678 1,858,208 2,186,581 3,234,777
Total Operating Loss (938,678) (1,800,728) (2,186,581) (2,898,669)
Other Income (Expense):        
Research and development credit 281 281
Interest expense (50,319) (51,353) (103,365) (115,014)
Total Other Expense, Net (50,038) (51,353) (103,084) (115,014)
Net Loss (988,716) (1,852,081) (2,289,665) (3,013,683)
Net Loss attributable to noncontrolling interest (6,150) (37,661) (16,645) (59,155)
Net Loss attributable to common stockholders $ (982,566) $ (1,814,420) $ (2,273,020) $ (2,954,528)
Basic Loss Per Common Share $ (0.00) $ (0.00) $ (0.01) $ (0.01)
Diluted Loss Per Common Share $ (0.00) $ (0.00) $ (0.01) $ (0.01)
Weighted Average Number of Common Shares Outstanding - Basic 420,279,879 420,279,879 420,279,879 420,279,879
Weighted Average Number of Common Shares Outstanding - Diluted 420,279,879 420,279,879 420,279,879 420,279,879